- This meta-analysis suggests that high-dose tigecycline (HDT) treatment demonstrated better clinical outcomes in the treatment of severe infections compared with standard-dose tigecycline and other non-tigecycline-containing regimens.
Why this matters
- HDT is recommended to patients with multidrug-resistant bacterial infections if a tigecycline-containing regimen is the clinical choice for severe infections.
- 10 studies (n=593) met eligibility criteria after a search across electronic databases.
- Primary outcome: all-cause mortality.
- Secondary outcomes: clinical cure rate, microbiological eradication rate, and adverse events.
- Funding: Conch Hospital.
- HDT vs placebo group had:
- lower all-cause mortality (OR, 0.44; 95% CI, 0.30-0.66; P<.0001>
- higher clinical cure (OR, 3.43; 95% CI, 2.09-5.63; P<.00001 and microbiological eradication rate ci p=".0003).</li">
- hospital-acquired pneumonia (OR, 0.39; 95% CI, 0.22-0.70; P=.002);
- blood stream infections (OR, 0.19; 95% CI, 0.06-0.58; P=.004); and
- mixed infections (OR, 0.20; 95% CI, 0.07-0.59; P=.003).
- Most of the studies were observational.
- Small sample size.